The effects of bovine growth hormone and thyroxine on growth rate and carcass measurements in lambs

The effects of bovine growth hormone (GH) and thyroxine (T4) on growth and carcass characteristics were assessed in Dorset ram lambs. Lambs in four groups (n = 10/group) were treated for 30 d as follows: controls, 3.33 mg (6 IU) GH/d (s.c.); 5-mg T4 implant (s.c.) on d 1 and a 10-mg T4 implant 21 d later; GH + T4. Blood samples were collected at 3-d intervals for analysis of GH, T4, triiodothyronine, somatomedin-C and testosterone concentrations. Six lambs/group were slaughtered for carcass measurements and composition. Daily GH injections increased (P less than .005) baseline plasma GH levels 10-fold, whereas plasma T4 concentrations were increased 10% (P less than .10) by the implants. Somatomedin-C increased with time in all groups, but the increments from d 0 to d 30 were higher (P less than .05) with GH treatment. Average daily gain (mean = 352 g/d), feed consumption and feed to gain ratio were not affected (P greater than .1) by GH or T4 treatment in ram lambs. Hot carcass weight and dressing percentage were increased (P less than .05) by T4. Growth hormone increased carcass protein content (P less than .005) and muscle weights while reducing carcass fat (P less than .05). Carcass composition was not altered by T4 alone, and the T4 x GH interaction was not significant; however, the combination of T4 and GH resulted in greater muscle and protein weight than did either hormone alone or no hormone administration. There were no differences in bone length or in the metacarpal growth plate width among groups. The beneficial effects of GH on carcass composition were not further enhanced by administration of thyroxine.     

Growth performance, serum hormones, and metabolite responses before and after weaning in lambs weaned at 42 days of age: effect of preweaning milk and postweaning alfalfa or grass hay diets.

Fourteen fall-born lambs were used to determine the effects of diet before and after weaning on intake, growth, serum hormones, and metabolite profiles. Before weaning, lambs were intensively sampled for 6 h at 35 and 42 d of age. Before sample collection, lambs were allowed to suckle, and milk intake was recorded. At 42 d of age, lambs were weaned and randomly allotted to ad libitum access to either alfalfa or grass hay. Blood samples were collected at 49 and 56 d of age for 6 h. Milk intake did not differ (P greater than .10) between groups. After weaning, lambs fed alfalfa hay consumed more (P less than .05) hay and had greater (P less than .05) ADG than lambs fed grass hay. Postweaning diet had no effect (P greater than .10) on serum insulin, growth hormone (GH), insulin:GH ratio, prolactin, cortisol, glucose, or nonesterified fatty acids (NE-FA) concentrations. Lambs consuming alfalfa had higher (P less than .05) serum urea nitrogen (SUN) at 49 and 56 d of age than lambs consuming grass. At 35 and 42 d of age, (P less than .05) serum insulin and insulin:GH ratio were higher (P less than .05) after milk intake than at 49 and 56 d of age after hay intake. Serum GH was higher (P less than .05) in lambs at 35 and 42 d of age for 2 h postfeeding, but by h 3 through 5, lambs consuming milk had lower (P less than .05) values than lambs consuming hay.(ABSTRACT TRUNCATED AT 250 WORDS)     

Effects of plane of nutrition, growth hormone and unsaturated fat on growth hormone, insulin and prolactin receptors in prepubertal lambs

The influence of plane of nutrition, growth hormone (GH) treatment and dietary polyunsaturated fat on serum concentrations of GH and insulin (INS) and binding capacities of GH, INS and prolactin (PRL) in liver, mammary parenchyma and adipose tissue was assessed in prepubertal ewe lambs. Ten lambs were assigned to each of four treatment groups. Treatments included: (A) lambs with ad libitum access to a high-energy ration; (G) lambs fed as group A and treated with bovine GH (.08 mg/kg/d); (R) lambs with feed intake restricted to limit ADG to about 120 g; and (S) lambs with ad libitum access to a ration including formaldehyde-protected sunflower seed. Diets, all approximately isonitrogenous and isocaloric, were fed from about 7 to 22 wk of age. Weekly blood samples were collected during wk 6 to 14 of the trial. Averaged across sampling dates, mean serum concentrations of GH were elevated in G lambs (P less than .05) and INS concentrations differed in the order G greater than A greater than R = S (P less than .05). Crude membranes for binding assays were prepared from liver, mammary parenchyma and adipose tissue. Mean concentrations of GH receptors in liver and PRL receptors in mammary parenchyma were elevated in group S lambs (P less than .01). Dietary polyunsaturated fat increased the number of GH receptors in liver and PRL receptors in mammary parenchyma. Increased availability of receptors may mediate the stimulation of mammary growth observed in lambs fed polyunsaturated fat.     

The effect of zeranol on live weight gain, feed intake and carcass composition of steers during compensatory growth

To evaluate the effect of zeranol implants in steers on compensatory ++growth, 80 steer calves (9 mo of age; 200 kg) were fed at two feeding levels (RO = 9.2 MJ ME/kg DM; R1 = 6.9 MJ ME/kg DM) for 119 d (Period 1). During Period 2, steers were full-fed to 400 kg BW with (Z1) or without (ZO) zeranol implants. Ten steers were slaughtered at the end of Period 1 to estimate carcass composition. Differences of 100 kg in BW were achieved by restriction in Period 1. Subsequent to restriction, cumulative ADG remained greater (P less than .05) up to the 24th wk of recuperation and implants increased (P less than .001) BW gain by 31% and 24% for RO and R1, respectively. The average daily energy intake (ME/W(.75) in Period 2 was similar for all treatments. Feed conversion was improved by 21.5% (P less than .05) by implants. At the end of Period 2 the R1ZO had 8.6 kg less muscle (P less than .001), 2.9 kg less bone (P less than .001) and 5.9 kg more fat (P less than .05) than the ROZO. In comparison, the carcasses of the implanted animals did not show significant differences (P greater than .05) due to restriction. Carcass daily gains were increased by previous restriction (P less than .01) and implants (P less than .05). Zeranol increased daily live weight gain and feed conversion in animals in continuous growth as well as in those observed in compensatory growth an tended to eliminate a tendency for higher content of fat in carcasses of nonimplanted animals making compensatory growth.     

Influence of zeranol and breed on growth, composition of gain, and plasma hormone concentrations

Seven Angus and six Brangus steers averaging 225 and 245 kg, respectively, were assigned randomly to zeranol (36 mg) implant (I) and no implant (NI) treatments. Steers had ad libitum access to a corn silage diet plus .68 kg of a soybean meal-based supplement fed daily. Steers were bled via jugular catheters on d 0, 28, 56, and 84 at 15-min intervals for 4 h before and 4 h after feeding. Concentrations of growth hormone (GH), insulin (INS), triiodothyronine (T3), thyroxine (T4), and glucose were determined. Whole-body protein and fat contents were monitored. A breed x I interaction (for d 56 to 84 and d 0 to 84) was observed for ADG (P less than .05 and P less than .07, respectively), feed conversion (P less than .05 and P less than .07, respectively), and protein deposition (for d 0 to 29 and d 0 to 84; P less than .07 and P less than .05, respectively). These interactions were attributed to a greater response to I by Angus than by Brangus steers. A feeding x period interaction (P less than .10) was observed for mean GH concentration, and INS, T4, and T3 concentrations were higher (P less than .05) during the 4-h postfeeding period than during the 4-h prefeeding period. The implant increased (P less than .08) mean GH concentration but did not alter the frequency, duration, or amplitude of plasma GH peaks. Steers that were implanted had lower (P less than .05) plasma T3. Brangus steers had lower (P less than .05) plasma glucose, T3, and T4 concentrations than Angus steers. Results indicate that growth factors beyond those measured are responsible for the anabolic response to zeranol.     

Effects of thyrotropin-releasing hormone and a thyrotropin releasing hormone analog on growth and selected plasma hormones in lambs

An 8-wk growth trial was conducted to assess the effects of continuous infusion of thyrotropin-releasing hormone (TRH) and an active TRH analog less than Aad-His-Pro-NH2 (the less than Aad is L-pyro-alpha-aminoadipic acid) on growth trial performance, carcass composition and hormone profiles of growing lambs. Both drugs were infused at 600 micrograms X lamb -1 X d -1 with 16 lambs/treatment. Both TRH and less than Aad-His-Pro-NH2 decreased average daily gain (ADG; P less than .01) and increased feed conversion (FC; P less than .01) compared with saline infused controls. Average daily feed intake was not altered. Carcasses of lambs given TRH or less than Aad-His-Pro-NH2 contained fewer kilograms of moisture (P less than .05) and appeared to contain fewer kilograms of protein. Thyrotropin-releasing hormone and less than Aad-His-Pro-NH2 increased thyroid gland weights (P less than .05), but pituitary gland weights were not different. Plasma thyrotropin (TSH) concentrations were increased by both drugs compared with control lambs, peaking at 4 to 7 d after initiating infusion. However, by 14 d, TSH concentrations returned to control levels. Triiodothyronine (T3) and thyroxine (T4) were elevated by both drugs over the entire 8-wk trial, with peak levels reached at 10 d and maintained for the duration of the study. Both TRH and less than Aad-His-Pro-NH2 increased prolactin over the entire period. Growth hormone levels were not altered by either drug. The effects of less than Aad-His-Pro-NH2 infusion on growth trial performance, carcass composition and hormone profiles of growing lambs were very similar to TRH. The negative effects of TRH and less than Aad-His-Pro-NH2 infusion on ADG, FC and carcass protein appear to be the result of elevated T3 and T4 levels.     

Effects of zeranol on in vitro growth hormone release by lamb and rat pituitary cells

A series of experiments was conducted to evaluate the effect of zeranol on release and synthesis of growth hormone (GH) by anterior pituitary cells established in either static or continuous flow cultures. Young adult male rats, slaughter-age lambs and juvenile lambs were used as sources of pituitary cells. In static primary cell cultures, no consistent effect of zeranol at 10(-7), 10(-9) or 10(-11) M was demonstrated by either rat or ovine cells. Rat pituitaries established in perifusion culture chambers showed no repeatable response to zeranol. Dissociated cells from lambs established in perifusion culture, however, had significant increases in release of GH in response to 37% of zeranol pulse exposures. When dissociated cells from juvenile lamb pituitaries were used, up to 10-fold increases in GH release consistently were measured within minutes of exposure to zeranol.     

Exogenous human growth hormone-releasing factor and ovine somatotropin improve growth performance and composition of gain in lambs

The objectives of this study were 1) to compare intermittent subcutaneous administration of human growth hormone-releasing factor (hGRF) at two doses with a similar regimen of ovine somatotropin (oST) for effects on growth and composition of gain in growing lambs and 2) to determine whether increasing the dietary amino acid availability enhances response to oST or hGRF. Eighty crossbred ewe and wether lambs (25.5 kg live weight) were assigned randomly in pairs to receive four daily injections of excipient, 40 micrograms oST/kg BW, 5 micrograms hGRF/kg BW or 10 micrograms hGRF/kg BW for 42 (n = 80) or 56 (n = 40) d. Doses were adjusted weekly for BW. Mean plasma oST concentrations increased from 2.03 ng/ml prior to treatment to 20.64, 4.80 and 5.45 ng/ml with oST, 5 and 10 micrograms/kg hGRF doses, respectively. Lambs did not become refractory to hGRF. Cumulative gain increased approximately 18% with 7 wk of treatment with oST and the low dose of hGRF (both P less than .01), and feed efficiency improved 21% with oST and 18% with both doses of hGRF (both P less than .05). Carcass lipid accretion rate decreased 22% to 30% (P less than .001), and carcass protein accretion rate increased 30% to 36% (P less than .001) with hGRF and oST treatment, respectively. Addition of fishmeal to the diet at 4% to replace an equal amount of soy protein improved gain 8.5%; it improved efficiency 14.2% (P less than .05) across all treatments, and it significantly enhanced the effects of oST on feed efficiency (interaction P less than .12) and hind leg muscle weights.     

Elimination of [14C]heptachlor from body stores of lactating ewes treated with ovine growth hormone

Elimination of [14C]heptachlor from body burdens of sheep was measured using mature ewes nursing single offspring, and the influence of exogenous ovine growth hormone (oGH) on elimination was studied. Six ewes (62 +/- 2.5 kg BW) were dosed (i.p.) once with [14C]heptachlor (2.04 mg/kg Bw; .88 microCi/mg heptachlor) and three were treated additionally with oGH (oGH; 5 mg/d) for 21 d. Three additional ewes served as controls. Excreta were collected each day for 21 d. Milk and blood were collected every 3rd d until ewes were euthanized at d 21. 14C activity was measured in excreta, milk, blood and tissues. Total cumulative activity of [14C]heptachlor and(or) metabolites in excreta (21 d) did not differ (P greater than .20) in ewes given oGH (25 +/- 2%) vs none (23 +/- 2%). Milk yield and protein content were unaffected (P greater than .10) by oGH. Ewes given oGH eliminated 2.2 +/- 2% of total 14C dosage into milk during 21 d, whereas ewes untreated with oGH eliminated 1.3 +/- .2% (P less than .10); total 14C activity eliminated into milk plus excreta was similar for ewes given oGH or none (P greater than .10). For all six ewes, half-times (T1/2) for distribution and elimination of 14C activity (heptachlor and metabolites) were 1.5 d and 11.7 d, respectively. Blood concentrations of 14C activity during 21 d yielded elimination half-time as 23 d. Unlike bovines, which eliminate heptachlor slowly (T1/2 approximately 70 to 80 d) and mainly into milk fat, lactating ovines eliminated heptachlor and(or) metabolites mainly into excreta and about sixfold faster than bovines.     

Effects of ovine growth hormone and other anterior pituitary hormones on lipolysis of rat and ovine adipose tissue in vitro

Ovine growth hormone ( oGH ) was tested for its effects on lipolysis of rat and ovine adipose tissue in vitro. Ovine growth hormone at 1, 5 and 25 micrograms/ml stimulated lipolysis (P less than .05) of chopped rat adipose tissue and isolated rat adipocytes incubated in the presence of 100 mU/ml adenosine deaminase and .2 micrograms/ml dexamethasone, but had no effect on lipolysis of chopped ovine adipose tissue or isolated ovine adipocytes. Isoproterenol, a beta-adrenergic agonist, stimulated lipolysis (P less than .05) of both rat and ovine adipose tissue. Contaminants of the oGH preparation used were examined for lipolytic effects. Thyroid-stimulating hormone (TSH), luteinizing hormone (LH) and adrenocorticotropic hormone (ACTH) content in oGH were measured by radioimmunoassay. When quantities of these hormones contaminating 5 and 25 micrograms oGH were tested for lipolysis in rat adipose tissue, the TSH contamination could account for some (30%) of the lipolysis observed with oGH , while the other hormones had no effect. Also, preincubation of oGH with anti-GH, but not with anti-TSH or anti-LH, removed the principle in oGH responsible for the lipolytic effect on rat adipose tissue.(ABSTRACT TRUNCATED AT 250 WORDS)     

Rate, composition and efficiency of growth in feedlot steers reimplanted with growth stimulants

Eighty Charolais-cross steer calves (283 kg) were fed a moderately high-energy (2.89 Mcal ME/kg) diet for 189 d to examine the effects of reimplantation of 36 mg of zeranol (Ralgro) or 200 mg progesterone plus 20 mg estradiol benzoate (Synovex-S) on the rate, composition and efficiency of gain, skeletal size and carcass parameters in a comparative slaughter trial. The implant treatments included unimplanted controls (C), Ralgro initially (R1), Synovex-S initially (S1), Ralgro initially and a reimplant at 84 d (R2) and Synovex-S initially and a reimplant at 84 d (S2). Both implants increased (P less than .06) gains by 8.1% from 0 to 84 d. Ralgro and Synovex-S increased (P less than .01) daily gains by 11.5% and 25.2%, respectively, from 84 to 189 d. The duration of the response to a single implant appeared to be in excess of 140 d; thus, reimplantation did not further increase daily gains. Reimplantation did improve (P less than .05) feed utilization in Ralgro implanted steers, however. Ralgro and Synovex-S increased (P less than .01) the rate of empty body (EB) protein accretion by 14.1% and 24%, respectively, without affecting EB fat growth. The efficiency of protein gain per unit protein (P less than .05) or energy intake (P less than .04) was improved, but the efficiency of energy gain per unit energy intake was not affected by implantation. Carcass weights of implanted steers were 5% greater (P less than .04) when adjusted to an equal carcass fatness. Both growth stimulants increased hip height (P less than .02), wither height (P less than .08) and body length (P less than .08) over C steers at slaughter.     

Skeletal muscle protein synthesis and growth hormone secretion in young lambs treated with clenbuterol

To determine effects of clenbuterol (CB) on muscle protein turnover and growth hormone (GH) secretion, 16 crossbred wether lambs (14.4 kg) were randomized into two groups designated to receive daily oral boluses of gelatin capsules containing corn starch with either 0 (control, CTL) or 1.87 mg/kg body weight CB for either 14 (n = 8) or 28 d (n = 8). This calculates to be approximately 40 mg CB/kg diet. Lambs had ad libitum access to a 16% crude protein corn-soy diet and feed consumption (FC) was measured. After 14 and 28 d, lambs were slaughtered and semitendinosus (ST), longissimus (LD) and brachialis (BR) muscles were exercised, weighed and analyzed for protein (TP) content. For 6 h prior to slaughter of 28-d lambs, 2.5 microCi L-[U-14C]tyrosine/kg was infused intravenously, blood was sampled and plasma was analyzed for specific radioactivity of tyrosine. Plasma GH concentrations were assessed by radioimmunoassay. No differences due to treatment were found in FC, rate of gain or GH concentrations. Semitendinosus and BR weights of control lambs at 14 d did not differ between treatments. At 28 d, ST and BR weights of control lambs (58.8 and 18.5 g, respectively) were less (P less than .10) than those of lambs treated with CB (74.3 and 23.1 g, respectively). The TP per ST and BR at 28 d for control lambs was 71.5 and 85.1% (P less than .10) that of muscles of lambs treated with CB. Fractional protein synthesis rates (FSR) of the BR (9.4 vs 6.1%/d) and total protein synthesized in ST muscle per day (1.4 vs .8 g) were elevated (P less than .10) in lambs treated with CB compared to controls. These data suggest that the increased fractional accretion rate observed in lambs treated with CB for 28 d was caused by increased FSR.     

Growth, carcass composition and selected hormone concentrations of restricted-and ad libitum-fed pigs

Two barrows and two gilts were selected from each of five different crossbred litters and allotted to either ad libitum- or restricted-fed treatments. Pigs fed at a level of 81% ad libitum intake grew slower (P less than .05), had less tenth-rib backfat (P less than .05), more percent muscle (P less than .05), an increased growth hormone (GH) secretion in response to glucose challenge at 50 kg (P less than .05) and decreased insulin secretion in response to glucose challenge at 50 and 100 kg (P less than .05) than ad libitum fed pigs. Hormone secretion response was also significantly affected by weight, with growth hormone decreasing and insulin increasing as pigs grew from 50 to 100 kg. No sex effects of sex X treatment interactions were found for hormone response (P greater than .10). There were no differences between treatments in feed efficiency, total feed intake on test, loin eye area, dressing percentage, or carcass length (P greater than .10). Carcass composition of barrows and gilts was affected differently by restricted nutrient intake.     

Influence of frame size and zeranol on growth, compositional growth and plasma hormone characteristics

A 2 X 2 factorially arranged trial was conducted to compare effects of implant (zeranol) and frame size on weight and compositional gain, and plasma hormone concentrations. Angus, Charolais X Hereford and Hereford X Angus yearling steers (34 steers averaging 270 kg body weight) were randomly assigned to treatments of small (SF) vs large frame (LF) and implant (I) vs no implant (NI). Steers were implanted at 0 and 97 d and individually fed an 81% whole shelled corn and 11.5% corn silage-based diet (dry basis) for a 175-d period. Shrunk weights and body measurements for frame size determination were taken initially and at approximately 28-d intervals; blood was collected via venipuncture at 14-d intervals for analyses of insulin (IN), triiodothyronine (T3), thyroxine (T4) and glucose concentrations. Steers were also counted in a whole body counter for measurement of 40K content and prediction of whole body protein and fat. The I steers showed an improvement (P less than .05) in daily gain regardless of frame size for the total trial. The I LF steers required 18% more dry matter to attain higher daily gain for 97 to 175 d; I steers were more efficient (P less than .05) at converting dry matter to gain during 0 to 97 d and 0 to 175 d. Daily fat deposition was increased (P less than .05) in I steers, while protein deposition was not affected by I. Plasma IN concentrations were numerically elevated (P less than .10) in I steers regardless of frame size, during the initial 97 d. Implant did not influence (P greater than .10) plasma T3, T4 and glucose concentrations regardless of frame size. Steers responded differently to zeranol implant over time regarding plasma T4 concentrations (P less than .003). Steers differing in frame size responded similarly in rate of gain, in feed conversion and in patterns of plasma insulin concentrations to zeranol implants.     

Postweaning growth, feed efficiency and chemical composition of sheep as affected by prenatal and postnatal testosterone

Data were collected from intact males, castrated males and ewe lambs to investigate the effect of presence or absence of testosterone prenatally and during the postweaning period on postweaning growth, feed intake and carcass chemical composition. Half the lambs from each sex were the progeny of dams that had received five injections of testosterone cyprionate from d 32 through d 87 of gestation. Linear contrasts were used to detect differences. Postweaning daily gain of intact males was greater (P less than .01) than that of male castrates. Ewe lambs from treated dams had approximately 12% greater rate of growth (P less than .04) than ewe lambs from control dams. Ewe lambs from dams that had been treated were 28% more efficient (P less than .01) in the conversion of food to weight than those from untreated dams. Ewe lambs from treated dams had heavier livers (P less than .07). Carcass protein for intact males was greater (P less than .11) than for castrates, and extractable fat was less (P less than .05). Masculinization of growth characteristics of ewe lambs affected the quantity of carcass fat relative to control ewes (7.59 vs 8.92 kg). These ewe lambs also had more water in the carcass than did the control ewes (13.93 vs 12.29 kg). Administration of exogenous testosterone to pregnant ewes over an interval of time approximating time of sexual differentiation in the fetus enhances postweaning growth rate, feed conversion efficiency and chemical composition of genetic females.     

Effect of long-term administration of porcine growth hormone-releasing factor and(or) thyrotropin-releasing factor on growth hormone, prolactin and thyroxine concentrations in growing pigs

Long-term administration of porcine growth hormone-releasing factor (pGRF(1-29)NH2) and(or) thyrotropin-releasing factor (TRF) was evaluated on serum concentrations of growth hormone (GH) thyroxine (T4) and prolactin (PRL). Twenty-four 12-wk-old female Yorkshire-Landrace pigs were injected at 1000 and 1600 for 12 wk with either saline, pGRF (15 micrograms/kg), TRF (6 micrograms/kg) or pGRF + TRF using a 2 x 2 factorial design. Blood samples were collected on d 1, 29, 57 and 85 of treatment from 0400 to 2200. Areas under the GH, T4 and PRL curves (AUC) for the 6 h (0400 to 1000) prior to injection were subtracted from the postinjection periods (1000 to 1600, 1600 to 2200) to calculate the net hormonal response. The AUC of GH for the first 6 h decreased similarly (P less than .05) with age for all treatments. The GH response to GRF remained unchanged (P greater than .10) across age. TRF alone did not stimulate (P less than .05) GH release but acted in synergy with GRF to increase (P less than .05) GH release. TRF stimulated (P less than .001) the net response of T4 on all sampling days. Animals treated with the combination of GRF + TRF showed a decreased T4 AUC during the first 6 h on the last three sampling days. Basal PRL decreased (P less than .05) with age. Over the four sampling days, animals injected with TRF alone showed (P less than .01) a reduction (linear effect; P less than .01) followed by an increase (quadratic effect; P less than .05) in total PRL concentration after injection; however, when GRF was combined with TRF, such effects were not observed (P greater than .10). Results showed that 1) chronic injections of GRF for 12 wk sustained GH concentration, 2) TRF and GRF acted synergistically to elevate GH AUC, 3) TRF increased T4 concentrations throughout the 12-wk treatment period, 4) chronic TRF treatment decreased the basal PRL concentration and 5) chronic GRF + TRF treatment decreased the basal concentration of T4.     

Feed efficiency, growth rates, body composition, milk production and milk composition of Targhee sheep selected for increased weaning weight

Lactation and growth of three contemporary lines of grade Targhee sheep developed from the same genetic base were characterized by three experiments performed over a period of 2 yr. Two lines (HW and DH) had been selected for 120-d weaning weights for 24 yr prior to beginning these experiments. A third line (C) was a randomly selected control. Year I experiment contrasted 10 DH with 7 C ram lambs fed to 58 kg. Year II experiments utilized 9 C, 14 DH and 10 HW ram lambs and 11 ewes suckling twins from each line. All Year II ram lambs were born and weaned as twins, then fed to 50 kg. Mature DH and HW ewes were heavier (P less than .05) than C ewes (65.2 and 68.8 vs 54.9 kg), and the DH and HW lambs grew faster than C lambs both before (P less than .05) and after weaning (P less than .05). While both DH and HW lambs drank more milk (2,419 and 2,368 vs 2,059 g X d-1 X pair-1; P less than .10) only HW ewes showed a trend towards greater potential milk production than controls (HW = 2,774 vs C = 2,155 g X d-1 X ewe-1 P less than .12). The HW lambs tended to be leaner than C lambs (P less than .05), but DH lambs did not differ from either line. Lambs from DH and HW lines required less post-weaning feed (121.9 and 129.3 vs 152.0 kg P less than .05) and exhibited 17 and 16% greater weight per day of age at 50 kg than controls (P less than .05). The DH line displayed lower feed: gain ratios than controls in both post-weaning trials (6.68 vs 7.30 to 58 kg; 5.83 vs 6.24 at 50 kg; P = .06).     

Serum prolactin and growth hormone responses to naloxone and intracerebral ventricle morphine administration in heifers

These studies examined responses of serum prolactin (PRL) and growth hormone (GH) to opioid agonist and antagonist administration in heifers. To minimize nonspecific and behavioral effects and to facilitate future studies with specific opioid receptor agonists, a cannula was placed within the third cerebral ventricle of the brain of 4- to 10-mo-old heifers to directly access hypothalamic regions involved in the regulation of PRL and GH secretion. Increasing doses of morphine (M) from 2 to 1,500 micrograms injected into the third cerebral ventricle increased (P less than .001) serum PRL concentrations in a dose-related manner. Growth hormone responses were variable, resulting in elevated (P less than .05) serum concentrations following morphine, but no dose-related effects were apparent. Both PRL and GH responses to 700 micrograms M were absent when an intracerebral ventricle injection of an equimolar dose of naloxone, an opioid receptor antagonist, was administered prior to M. In a replicated 4 x 4 latin square, the effects of intravenous naloxone on PRL and GH responses was tested in young (86 +/- 11 d) and older (234 +/- 6 d) heifers. Naloxone at doses of 1, 2 and 4 mg/kg reduced (P less than .05) serum concentrations of PRL for 45 to 60 min. Mean concentrations of GH tended to be higher (P less than .07) in older heifers All doses of naloxone decreased (P less than .05) serum GH concentrations in older heifers but proved ineffective in younger heifers. There were no differences between doses of naloxone on either PRL or GH. These data suggest that endogenous opioids are involved in the regulation of PRL and GH secretion in heifers.     

Effects of dietary level of ruminally protected choline on performance and carcass characteristics of finishing beef steers and on growth and serum metabolites in lambs

Ruminally protected choline (RPC) was evaluated in two experiments. In Exp. 1, beef steers (n = 160; average initial BW = 350.9 kg) were fed a 90% concentrate diet with either 0, .25, .5, or 1.0% RPC (DM basis) for 112 to 140 d. Feeding .25% RPC increased ADG 11.6% compared with 0% RPC, but responses diminished with increasing RPC level (cubic response, P < .10). Daily DMI was not affected by RPC level, but feed:gain was improved 6.8% with .25% RPC compared with 0% RPC, and responses diminished with increasing RPC level (cubic response, P < .10). Carcass yield grade increased linearly (P < .10) as RPC level increased, but marbling score was lower for all three RPC-containing diets than for the 0% RPC diet (quadratic response, P < .05). In Exp. 2, 20 Suffolk lambs (initial BW = 29.8 kg) were fed an 80% concentrate diet for 56 d with the same RPC levels as in Exp. 1. Serum triglycerides (TG) and cholesterol (CLSTRL) were measured in weekly blood samples, and intensive blood samples were collected on d 28 and 56 to evaluate serum insulin (INS), GH, and NEFA. For the 56-d feeding period, ADG responded quadratically (P < .10) to RPC level, but DMI and feed:gain were not affected. Serum INS and NEFA concentrations increased linearly (P < .05) and serum GH responded cubically (P < .05) to RPC level on d 28, but no differences were noted on d 56. Serum TG concentrations in weekly samples increased linearly (P < .10) with RPC level, but, averaged over all weeks, serum CLSTRL concentrations did not differ (P > .10) among treatments. Quantities of carcass mesenteric (P < .05) and kidney fat (P < .10) increased linearly, but longissimus muscle and liver fat contents did not differ (P > .10) among RPC levels. Supplementing RPC in high-concentrate diets improved performance, but results were not consistent among RPC levels or between cattle and sheep. Potential effects of RPC might be mediated through alterations in fat metabolism and(or) metabolic hormones related to fat metabolism.     

Stimulation of pig growth performance by porcine growth hormone and growth hormone-releasing factor

The current study was undertaken to determine the effects of human growth hormone-releasing factor [hpGRF-(1-44)-NH2] on growth performance in pigs and whether this response was comparable to exogenous porcine growth hormone (pGH) treatment. Preliminary studies were conducted to determine if GRF increased plasma GH concentration after iv and im injection and the nature of the dose response. Growth hormone-releasing factor stimulated the release of pGH in a dose-dependent fashion, although the individual responses varied widely among pigs. The results from the im study were used to determine the dose of GRF to use for a 30-d growth trial. Thirty-six Yorkshire-Duroc barrows (initial wt 50 kg) were randomly allotted to one of three experimental groups (C = control, GRF and pGH). Pigs were treated daily with 30 micrograms of GRF/kg body weight by im injection in the neck. Pigs treated with pGH were also given 30 micrograms/kg body weight by im injection. Growth rate was increased 10% by pGH vs C pigs (P less than .05). Growth rate was not affected by GRF; however, hot and chilled carcass weights were increased 5% vs C pigs (P less than .05). On an absolute basis, adipose tissue mass was unaffected by pGH or GRF. Carcass lipid (percent of soft-tissue mass) was decreased 13% by GRF (P less than .05) and 18% by pGH (P less than .05). Muscle mass was significantly increased by pGH but not by GRF. There was a trend for feed efficiency to be improved by GRF; however, this was not different from control pigs. In contrast, pGH increased feed efficiency 19% vs control pigs (P less than .05). Chronic administration of GRF increased anterior pituitary weight but did not affect pituitary GH content or concentration. When blood was taken 3 h post-injection, both GRF- and pGH-treated pigs had lower blood-urea nitrogen concentrations. Serum glucose was significantly elevated by both GRF and pGH treatment. This was associated with an elevation in serum insulin. These results indicate that increasing the GH concentration in blood by either exogenous GH or GRF enhances growth performance. The effects of pGH were more marked than for GRF. Further studies are needed to determine the optimal dose of GRF to administer in growth trials and the appropriate pattern of GRF administration in order to determine whether GRF will enhance pig growth performance to the extent that exogenous pGH does.